

Ambrogio Orlando

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4932356/publications.pdf>

Version: 2024-02-01

94
papers

3,089
citations

185998

28
h-index

174990

52
g-index

95
all docs

95
docs citations

95
times ranked

3870
citing authors

#	ARTICLE	IF	CITATIONS
1	Mongersen, an Oral <i>SMAD7</i> Antisense Oligonucleotide, and Crohn's Disease. <i>New England Journal of Medicine</i> , 2015, 372, 1104-1113.	13.9	366
2	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 30-35.	2.4	316
3	Radiofrequency Thermal Ablation vs. Percutaneous Ethanol Injection for Small Hepatocellular Carcinoma in Cirrhosis: Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , 2009, 104, 514-524.	0.2	239
4	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2011, 43, 1-20.	0.4	125
5	The PROSIT-BIO Cohort. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 233-243.	0.9	116
6	Meta-Analysis of the Placebo Rates of Clinical Relapse and Severe Endoscopic Recurrence in Postoperative Crohn's Disease. <i>Gastroenterology</i> , 2008, 135, 1500-1509.	0.6	84
7	Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 822-830.	2.5	84
8	Inter-observer agreement in endoscopic scoring systems: Preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2014, 46, 969-973.	0.4	78
9	Adalimumab in active ulcerative colitis: A real-life observational study. <i>Digestive and Liver Disease</i> , 2013, 45, 738-743.	0.4	72
10	Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 9675.	1.4	70
11	The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. <i>Autoimmunity Reviews</i> , 2014, 13, 751-755.	2.5	67
12	Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1217-1221.	0.6	53
13	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 568-579.	0.9	51
14	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2017, 49, 604-617.	0.4	47
15	Gastrointestinal lesions associated with spondyloarthropathies. <i>World Journal of Gastroenterology</i> , 2009, 15, 2443.	1.4	42
16	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.4	42
17	Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 758-766.	0.9	41
18	Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e31-e31.	0.5	40

#	ARTICLE	IF	CITATIONS
19	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2014, 46, 963-968.	0.4	39
20	Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2013, 45, 986-991.	0.4	38
21	COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data. <i>Digestive and Liver Disease</i> , 2020, 52, 1222-1227.	0.4	38
22	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.4	36
23	The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 182-189.	0.9	35
24	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2016, 48, 360-370.	0.4	34
25	The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , 2018, 50, 675-681.	0.4	34
26	Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Caseâ€“Control IG-IBD Study. <i>Inflammatory Bowel Diseases</i> , 2019, 26, 450-459.	0.9	33
27	Effectiveness and safety of Ustekinumab for the treatment of Crohnâ€™s disease in real-life experiences: a meta-analysis of observational studies. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 193-203.	1.4	33
28	Anti-interleukin-12 and anti-interleukin-23 agents in Crohnâ€™s disease. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 89-98.	1.4	31
29	Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 913-924.	0.6	30
30	Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1805-1812.	0.9	30
31	A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-Î± Inhibitor-naïve and Non-naïve Patients With Crohnâ€™s Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 209-217.	0.6	30
32	Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. <i>Journal of Infection</i> , 2017, 74, 433-441.	1.7	28
33	COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patientsâ€™ Association. <i>Inflammatory Bowel Diseases</i> , 2021, , .	0.9	28
34	Patient and physician views on the quality of care in inflammatory bowel disease: Results from SOLUTION-1, a prospective IG-IBD study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1642-1652.	0.6	27
35	Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jjw181.	0.6	27
36	Ustekinumab in the management of Crohnâ€™s disease: Expert opinion. <i>Digestive and Liver Disease</i> , 2018, 50, 653-660.	0.4	22

#	ARTICLE	IF	CITATIONS
37	Inflammatory Bowel Disease Onset During Secukinumab Treatment: Real Concern or Just an Expression of Dysregulated Immune Response?. <i>Clinical Drug Investigation</i> , 2019, 39, 799-803.	1.1	22
38	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2022, 54, 440-451.	0.4	22
39	Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-7.	0.6	21
40	Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multicentre study. <i>United European Gastroenterology Journal</i> , 2020, 8, 1045-1055.	1.6	21
41	Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Drugs and Aging</i> , 2020, 37, 383-392.	1.3	20
42	Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2019, 51, 510-515.	0.4	18
43	Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 987-997.	0.9	17
44	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , 2018, 35, 545-562.	1.3	16
45	The Addition of an Immunosuppressant After Loss of Response to Anti-TNF α Monotherapy in Inflammatory Bowel Disease: A 2-Year Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 394-401.	0.9	16
46	A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1292-1298.	0.4	16
47	A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. <i>Digestive and Liver Disease</i> , 2020, 52, 1461-1466.	0.4	16
48	Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis?. <i>Journal of Clinical Virology</i> , 2017, 97, 1-3.	1.6	15
49	Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases. <i>JGH Open</i> , 2021, 5, 364-370.	0.7	15
50	Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. <i>Digestive and Liver Disease</i> , 2019, 51, 613-620.	0.4	14
51	Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn's Disease. <i>Digestive and Liver Disease</i> , 2019, 51, 640-647.	0.4	14
52	Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality. <i>Digestive and Liver Disease</i> , 2020, 52, 506-515.	0.4	14
53	A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 105-111.	1.4	14
54	SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3041-3049.	1.4	14

#	ARTICLE	IF	CITATIONS
55	Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. <i>Digestive and Liver Disease</i> , 2017, 49, 1298-1305.	0.4	13
56	Physicians's Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestion</i> , 2020, 101, 433-440.	1.2	13
57	Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110106.	1.4	13
58	The biologics of ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 175-184.	1.4	12
59	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-9.	0.7	12
60	Adalimumab in steroid-dependent Crohn's disease patients: Prognostic factors for clinical benefit. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 826-831.	0.9	11
61	Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1102-1106.	0.6	11
62	Prevalence and incidence of inflammatory bowel disease in two Italian islands, Sicily and Sardinia: A report based on health information systems. <i>Digestive and Liver Disease</i> , 2019, 51, 1270-1274.	0.4	11
63	Effectiveness and safety of biologics in pediatric inflammatory bowel disease: Real-life data from the Sicilian Network. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 223-229.	0.7	11
64	Ustekinumab for treating ulcerative colitis: an expert opinion. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1321-1329.	1.4	11
65	Toxic megacolon and human Cytomegalovirus in a series of severe ulcerative colitis patients. <i>Journal of Clinical Virology</i> , 2015, 66, 103-106.	1.6	10
66	The METEOR Trial: The Burial of Methotrexate in Ulcerative Colitis?. <i>Gastroenterology</i> , 2016, 151, 211-212.	0.6	9
67	Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 217-221.	0.9	9
68	Selective Use of Combination Therapy in Patients With Infliximab-resistant Inflammatory Bowel Disease: Data From a Tertiary Referral Center. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 914.	2.4	8
69	Letter: SPOSIB SB2's a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 234-236.	1.9	8
70	Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1381-1384.	1.4	8
71	A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 203-223.	1.4	8
72	The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1451-1451.	0.6	7

#	ARTICLE	IF	CITATIONS
73	Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. Digestive and Liver Disease, 2020, 52, 44-50.	0.4	7
74	Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease. Digestive and Liver Disease, 2020, 52, 1304-1309.	0.4	7
75	Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies. Digestive and Liver Disease, 2022, 54, 183-191.	0.4	7
76	Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study. Digestive and Liver Disease, 2016, 48, 1314-1317.	0.4	6
77	Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders. Digestive and Liver Disease, 2016, 48, 1506-1509.	0.4	6
78	Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF- α inhibitors and conventional immunosuppressants. Digestive and Liver Disease, 2017, 49, 157-162.	0.4	6
79	Unmet needs of Italian physicians managing patients with inflammatory bowel disease. Digestive and Liver Disease, 2019, 51, 212-217.	0.4	6
80	Risk of Pneumonia Caused by Pneumocystis jiroveci in Inflammatory Bowel Disease: The Role of Concomitant Pulmonary Comorbidities. Clinical Gastroenterology and Hepatology, 2019, 17, 571-572.	2.4	6
81	Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?. Gastroenterology, 2021, 160, 1877-1878.	0.6	6
82	Increased risk of pneumonia among patients with inflammatory bowel disease: A comparison between patients treated with biologic therapies and with conventional drugs. Journal of Crohn's and Colitis, 2013, 7, e405-e406.	0.6	5
83	Incident Colorectal Cancer in Inflammatory Bowel Disease. Cancers, 2022, 14, 721.	1.7	5
84	Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients. Infection, 2019, 47, 409-415.	2.3	4
85	How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey. Digestive and Liver Disease, 2018, 50, 734-736.	0.4	3
86	Barriers to anti-TNF α prescription among Italian physicians managing inflammatory bowel disease. GastroHep, 2019, 1, 93-99.	0.3	3
87	Herpes Zoster Eruption During Vedolizumab Therapy: A Simple Coincidence or More?. Inflammatory Bowel Diseases, 2020, 26, e51-e52.	0.9	3
88	Endoscopic rescue treatment in a pregnant ulcerative colitis patient with a severe colonic stricture: a conservative approach to bring the pregnancy to term. Gastrointestinal Endoscopy, 2017, 86, 1183-1185.	0.5	2
89	Letter: psoriasiform eruption during vedolizumab therapy. Alimentary Pharmacology and Therapeutics, 2019, 50, 342-343.	1.9	2
90	Anti-TNF combination therapy in inflammatory bowel disease: de novo or selective?. Minerva Gastroenterologica E Dietologica, 2020, 65, 291-297.	2.2	2

#	ARTICLE	IF	CITATIONS
91	Ozanimod for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2022, 386, 194-195.	13.9	2
92	Letter: propensity score—handle with care. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 360-361.	1.9	2
93	Epidemiological trends in pediatric inflammatory bowel disease: The precious contribution of the registries promoted by scientific societies. <i>Digestive and Liver Disease</i> , 2022, , .	0.4	1
94	The VERSIFY Trial: What About Ultrasound Assessment?. <i>Gastroenterology</i> , 2020, 158, 1176-1177.	0.6	0